ABPI Lauds MHRA’s 2014-2015 Business Plan

The UK’s Medicines and Healthcare products Regulatory Agency’s 2014-2015 business plan, released this week, supports safe innovation, UK growth, safety and vigilance, says Association of the British Pharmaceutical Industry CEO Stephen Whitehead.

Steps such as implementing the EU Clinical Trials regulation, producing a budget that reduces costs and coming out with a marketing and business development plan will achieve the MHRA’s stated objectives for the coming year, among which are:

• Supporting innovation and growth;

• Bolstering science;

• Improving pharmacovigilance;

• Extending outreach;

• Developing new products and services;

• Improving relationships with providers and the public; and

• Supporting its staff and growing its business intelligence.

The agency also aims to assess 97 percent of marketing authorizations from the UK within 150 days and from European companies within the allotted time.

Read the business plan at www.fdanews.com/ext/resources/files/04/04-18-14-MHRABusinessPlan.pdf. — Lena Freund

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.